We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Skytrofa

News List

FDA Approves Skytrofa (lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Pediatric Growth Hormone Deficiency drugs
August 26, 2021
Ascendis Pharma A/S today announced that the U.S. Food and Drug Administration (FDA) has approved Skytrofa (lonapegsomatropin-tcgd) for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) .
US clears Ascendis' once-weekly paediatric growth hormone injection firstwordpharma
August 26, 2021
Ascendis Pharma said Wednesday that the FDA has approved Skytrofa (lonapegsomatropin-tcgd) as a once-weekly treatment for paediatric patients aged one year and older who have growth failure due to inadequate secretion of endogenous growth hormone.